December 27th 2018

NEWS RELEASE
Company:KYORIN Holdings, Inc.
Representative: Minoru Hogawa
Representative Director, President(Security Code: 4569, TSE 1st Sec.)Contact:Shuji Miyaki
Director, Corporate Communication
President OfficeTelephone:(0)3-3525-4707
Hebrew University to Collaborate with KYORIN
Strategic partnership aims to develop respiratory drug therapies
December 27th, 2018, KYORIN Pharmaceutical Co., Ltd. (Tokyo, Japan), a subsidiary of KYORIN Holdings,
Inc., which is engaged in the development and commercialization of prescription drugs and Yissum, theTechnology Transfer Company of The Hebrew University of Jerusalem, announced today a strategic
collaboration in the discovery of respiratory drug therapies. Under the collaboration, KYORIN willsponsor a research program led by Prof. Francesca Levi-Schaffer of Hebrew University’s Institute of Drug
Research in the School of Pharmacy, Faculty of Medicine and advance its own drug discovery researchwith the outcome from the program.
Prof. Levi-Schaffer specializes in the area of immunopharmacology for allergies. Her research focuses onmast cells and eosinophils, the main effector cells in allergic diseases such as asthma and atopic
dermatitis. KYORIN focuses on R&D and commercialization of prescription drugs, and respiratory field is
positioned as one of its franchises. In the new partnership, KYORIN and Prof. Levi-Schaffer will
collaborate and screen for new drugs based on her expertise of allergic inflammation. As such, newpotential targets for the suppression of asthma and other related indications will be identified.
For KYORIN, this international network with academic collaboration in research is significant and thisopportunity to form cooperative research relationships for first-in- class drugs on various respiratory
diseases will enhance our research capabilities for drug seeds discovery.
About KYORIN
Trusted among patients and professionals in the medical industry, KYORIN strives to be a company that
contributes to the public health and is recognized as a one with social significance by improving its
presence in specified therapeutic areas and through global discovery of novel drugs. KYORIN uses its
sales and marketing strategy in focusing on respiratory, otolaryngology and urology, and concentrates
resources on the innovative drug discovery activities in its own research, with supplementing andstrengthening external drug discovery programs and technology platforms from academic institutions,venture start-ups, and domestic and international drug discovery companies, as open innovation
partnership. For further information please visit www.kyorin-pharm.co.jp/en/
About Yissum
Yissum is the technology transfer company of The Hebrew University of Jerusalem. Founded in 1964, itis the third company of its kind to be established and serves as a bridge between cutting-edge academic
research and a global community of entrepreneurs, investors, and industry. Yissum’s mission is tobenefit society by converting extraordinary innovations and transformational technologies into
commercial solutions that address our most urgent global challenges. Yissum has registered over

10,000 patents covering 2,800 inventions; licensed over 900 technologies and has spun out more than
135 companies. Yissum’s business partners span the globe and include companies such as Boston
Scientific, Google, ICL, Intel, Johnson & Johnson, Merck, Microsoft, Novartis and many more. For further
information please visit www.yissum.co.il